Axsome Therapeutics
AXSM
111 hedge funds and large institutions have $387M invested in Axsome Therapeutics in 2019 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 46 increasing their positions, 24 reducing their positions, and 20 closing their positions.
92% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 24
81% more call options, than puts
Call options by funds: $29.4M | Put options by funds: $16.2M
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
2% more funds holding
Funds holding: 109 → 111 (+2)
0.15% less ownership
Funds ownership: 55.12% → 54.97% (-0.15%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
19% less capital invested
Capital invested by funds: $477M → $387M (-$89.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$10.3M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$6.24M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
+$5.4M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.25M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$17.4M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$12.5M |
| 3 |
Renaissance Technologies
New York
|
-$6.37M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$4.5M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.36M |
AXSM Hedge Fund Activity: Q3 2019 in Review
111 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q3 2019, worth a combined $387M — down 19% from $477M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new AXSM positions and 20 closed out — a net gain of 2 holders — while 46 added to existing stakes and 24 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $10.3M. The largest seller was RA Capital Management, cutting an estimated $17.4M.
- 111 institutional investors held Axsome Therapeutics (AXSM) as of Q3 2019, up from 109 in Q2 2019.
- Funds reported $387M of Axsome Therapeutics stock for Q3 2019, down 19% quarter-over-quarter.
- 22 funds opened new Axsome Therapeutics positions in Q3 2019 and 20 closed out, a net change of +2 holders.
- The largest Axsome Therapeutics buyer in Q3 2019 was Farallon Capital Management, an estimated $10.3M added.
- The largest Axsome Therapeutics seller in Q3 2019 was RA Capital Management, an estimated $17.4M sold.
Based on aggregated 13F filings for Q3 2019.